Findings

What do systematic reviews say?

4,736 questions · 15,265 findings · 1,163 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,871 · 25.4%GRADE not reported 810 · 5.3%Very low 4,242 · 27.8%Low 3,879 · 25.4%Moderate 1,999 · 13.1%High 464 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

All‐cause mortality · people with acute UGIH

It is very uncertain whether erythromycin plus nasogastric tube lavage changes all‐cause mortality compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 238 participants
Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

Visualisation of gastric mucosa · people with acute UGIH

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 170 participants
Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

NSAEs · people with acute UGIH

It is very uncertain whether erythromycin plus nasogastric tube lavage changes NSAEs compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
RD 0
6 studies · 408 participants
Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

Rebleeding · people with acute UGIH

It is very uncertain whether erythromycin plus nasogastric tube lavage changes rebleeding compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
RR 1.13 [0.63, 2.02]
1 study · 169 participants
Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

Blood transfusion · people with acute UGIH

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 180 participants
Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

UGIH‐related mortality · people with acute UGIH

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

SAEs · people with acute UGIH

1 finding from 1 review

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 408 participants
Very low

Intervention not reported

Total studies: 17 RCTs Total participants: 22,819 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 22819 participants
GRADE not reported

Intervention not reported

LD‐ICS/LABA (Direct evidence; 0 RCTs; 0 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
Low

Intervention not reported

MD‐ICS/LAMA (Direct evidence; 2 RCTs; 679 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 679 participants
Low

Intervention not reported

MD‐ICS/LABA (Direct evidence; 12 RCTs; 7569 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 7569 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 2 RCTs; 1759 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1759 participants
Moderate

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 4 RCTs Total participants: 5681 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 5681 participants
GRADE not reported

Intervention not reported

HD‐ICS (Direct evidence; 2 RCTs; 1005 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1005 participants
High

Intervention not reported

MD‐ICS/LABA (Direct evidence; 1 RCT; 774 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 774 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 2 RCTs; 2863 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2863 participants
High

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

HD‐ICS (Direct evidence; 4 RCTs; 3003 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 3003 participants
Moderate

Intervention not reported

Total studies: 6 RCTs Total participants: 4276 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LABA, or…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 4276 participants
GRADE not reported